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Abstract
Pain often accompanies cancer and most current therapies for treating cancer pain have significant unwanted side
effects. Targeting nerve growth factor (NGF) or its cognate receptor tropomyosin receptor kinase A (TrkA) has
become an attractive target for attenuating chronic pain.
In the present report, we use a mouse model of bone cancer pain and examine whether oral administration of a
selective small molecule Trk inhibitor (ARRY-470, which blocks TrkA, TrkB and TrkC kinase activity at low nm con-
centrations) has a significant effect on cancer-induced pain behaviors, tumor-induced remodeling of sensory nerve
fibers, tumor growth and tumor-induced bone remodeling. Early/sustained (initiated day 6 post cancer cell injec-
tion), but not late/acute (initiated day 18 post cancer cell injection) administration of ARRY-470 markedly attenu-
ated bone cancer pain and significantly blocked the ectopic sprouting of sensory nerve fibers and the formation of
neuroma-like structures in the tumor bearing bone, but did not have a significant effect on tumor growth or bone
remodeling.
These data suggest that, like therapies that target the cancer itself, the earlier that the blockade of TrkA occurs, the
more effective the control of cancer pain and the tumor-induced remodeling of sensory nerve fibers. Developing
targeted therapies that relieve cancer pain without the side effects of current analgesics has the potential to signif-
icantly improve the quality of life and functional status of cancer patients.
Background
Cancer pain can have a significant impact on the quality
of life and functional status of the individual [1,2]. A
major reason cancer pain remains a significant health
problem is the limited repertoire and negative side
effects of currently available analgesics. For example,
non-steroidal anti-inflammatory drugs, which are effec-
tive in reducing a variety of musculoskeletal pains, have
been shown to have significant gastrointestinal side
effects [3,4]. Opiates are also frequently used to treat
moderate to severe cancer pain. While opiates are highly
effective at controlling ongoing cancer pain, as a class
opiates have a variety of unwanted side effects including
increased somnolence, agitation, constipation, dizziness,
cognitive impairment and respiratory depression [5,6].
Recently, peripherally restricted targeting of nerve
growth factor (NGF) or its cognate tropomyosin recep-
tor kinase A (TrkA) has become an attractive target for
attenuating chronic pain. Four major strategies are cur-
rently being pursued (Figure 1) and each of these strate-
gies has its potential strengths and limitations [7,8]. For
example, while monoclonal antibodies (mAbs) are extra-
ordinarily specific in their targeting, administration of
mAbs carries the risk of immune reactions such as
acute anaphylaxis, serum sickness and the generation of
antibodies against the therapeutic agent. In contrast,
small molecule inhibitors of kinase activity do not
require intravenous or intramuscular injection, are
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greater flexibility in dosing, but are generally less selec-
tive than mAbs [8]. Whether the kinases’ lack of extra-
ordinary specificity found with mAbs will provide
greater desired efficacy or greater unwanted side effects
will probably need to be examined with each mAb or
kinase(s) that is being targeted.
In the present paper we use a mouse model of bone
cancer pain to demonstrate that early administration of
a small molecule kinase Trk inhibitor, ARRY-470, signif-
icantly reduces cancer pain in the early, middle and late
time points in disease progression. Interestingly, the
cancer and its associated stromal cells induced a
remarkable sprouting and neuroma formation by sen-
sory nerve fibers that innervate the tumor-bearing bone
and this sprouting and neuroma formation was mark-
edly attenuated by Trk inhibition. In contrast, Trk inhi-
bition had no significant effect on tumor growth or
tumor-induced bone remodeling in this model.
Results
Early, but not late ARRY-470 administration significantly
attenuates tumor-induced pain
To assess whether inhibition of the Trks attenuates bone
cancer pain, pain behaviors were analyzed in sham + vehi-
cle and in tumor-bearing mice treated with early/acute
ARRY-470, early/sustained ARRY-470, and late/acute
ARRY-470. These behavioral analyses confirmed previous
observations [9] that at early time points (days 8-14 post
tumor cell injection), pain-related behaviors gradually
increase in severity with time (Figure 2A), and correlate
with tumor growth in the intramedullary space of the
femur, as well as progressive tumor-induced bone destruc-
tion. Interestingly, pain behaviors escalated rapidly upon
the escape of sarcoma cells from the intramedullary space
(days 14-20 post tumor injection) (Figure 2A), which
resulted in tumor-induced sprouting of CGRP
+ and
Figure 1 Strategies for targeting NGF/TrkA for pain relief.
Current strategies for targeting NGF or its cognate receptor TrkA
include; monoclonal antibodies or peptibodies that sequester NGF
(1), monoclonal antibodies that target TrkA and prevent NGF from
binding to TrkA (2), small molecule TrkA antagonist therapy (3) and
the focus of the current study, a small molecule kinase inhibitor of
Trk’s (4). The Trk inhibitor used in this study (ARRY-470) is a small
molecule inhibitor demonstrating nanomolar cellular inhibition of
TrkA (6.5 nM), TrkB (8.1 nM), and TrkC (10.6 nM) and a high level of
selectivity over a panel of kinase and non-kinase receptors
(Additional file 1 Table S2 and S3). Schematic drawing adapted from
Pezet and McMahon [17].
Figure 2 ARRY-470 can significantly reduce bone cancer pain
behaviors. Injection of green fluorescent protein (GFP)
+ sarcoma
cells into the intramedullary space of the femur results in
significantly greater spontaneous flinching pain behaviors compared
to sham injected mice from day 8 until day 20 post cell injection
(A). Note that at day 14 there is a rapid escalation of pain behaviors,
which is when invasion and growth of GFP
+ cancer cells occurs
within the periosteum. ARRY-470 therapy significantly reduces
cancer pain behaviors if this therapy is administered before
sprouting and neuroma formation occur, in either an early/acute
(days 6-8), or an early/sustained (days 6-20) fashion (B). In contrast,
ARRY-470 administered at late time points (days 18-20), when nerve
sprouting and neuroma-like structures have already formed, did not
significantly reduce cancer-related spontaneous guarding pain
behaviors. Each point or bar represents the mean ± SEM. Brackets
indicate the groups being compared. *p < 0.01.
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+ nerve fibers in the periosteum. Behavioral analysis
revealed that when ARRY-470 was given from days 6-8
post tumor injection, pain behaviors were reduced by
~40% at day 8, whereas early/sustained administration of
ARRY-470 from days 6-20 reduced pain behaviors by
~60% at day 20. In contrast, late administration of ARRY-
470 (initiated at day 18-20) did not significantly reduce
cancer pain behaviors by day 20 (Figure 2B).
Tumor growth induces profuse sprouting of sensory
nerve fibers and the formation of neuroma-like structures
Tumor-induced changes were examined in the perios-
teum, as this bone compartment is richly innervated by
sensory nerve fibers [10], appears to be pivotally
involved in detecting injury to the skeleton [11], and is
the only tissue in bone that can be immunohistochemi-
cally analyzed in both decalcified frozen sections and
non-decalcified whole mount preparations [10]. In naïve
and sham + vehicle-treated animals CGRP
+ sensory
nerve fibers have a net-like organization and are typi-
cally associated with blood vessels. In sham mice, there
was no difference in the organization or density of
CGRP
+ (Figure 3A) periosteal nerve fibers compared to
naïve mice (data not shown). Twenty days following
tumor cell injection, we observed significant sprouting
by CGRP
+ and NF200
+ sensory nerve fibers. These
fibers appeared to be intermingled among GFP
+ tumor
cells, and had a disorganized appearance that is never
observed in the periosteum of naïve or sham mice.
Whereas all mice with GFP
+ tumor cells growing in
t h ep e r i o s t e u ms h o w e ds i g n i f i c a n ts p r o u t i n go fC G R P
+
and NF200
+ nerve fibers, approximately one half of
these mice had 1-2 neuroma-like structures in the peri-
osteum (Figure 4B, Figure 5B). These neuroma-like
structures appear as a disordered mass of blind ending
axons that have an interlacing or whirling morphology
[12,13] and are never observed in sham or naïve
animals.
Early blockade of Trk’s attenuates tumor-induced nerve
sprouting and formation of neuroma-like structures and
does not significantly affect disease progression
Early/sustained treatment with ARRY-470 (given twice
daily from 6 to 20 days post tumor injection) largely pre-
vented the sprouting of CGRP
+ (Figure 6C, Figure 7A)
and NF200
+ (Figure 6F, Figure 7B) nerve fibers. Interest-
ingly, the attenuation of this sprouting was observed only
with the early/sustained ARRY-470 administration, and
not with the late/acute administration (Figure 7A, B).
Early/sustained administration of ARRY-470 similarly
resulted in a marked decrease in the formation of neu-
roma-like structures of CGRP
+ and NF200
+ nerve fibers.
Importantly, early/sustained administration of ARRY-470
did not affect the organization or density of CGRP
+ or
NF200
+ fibers in the contralateral, non-tumor bearing
bones compared to sham mice (data not shown).
In addition, the effects of ARRY-470 therapy on tumor
growth and bone destruction were examined at day 14
and 20 post tumor injection, respectively. Treatment of
sarcoma-injected mice with ARRY-470 at days 6-20 post
tumor injection resulted in no reduction in tumor
growth (100 ± 0 of intramedullary space (Additional file
1 Figure S1B) and no significant change in bone resorp-
tion (2.6 ± 0.24; as compared to sarcoma + vehicle ani-
mals (2.8 ± 0.14) (Additional file 1 Figure S1E).
Discussion
Blockade of Trks and skeletal pain
In the present study we show that early/sustained
administration of a Trk inhibitor significantly inhibited
sprouting and neuroma formation by sensory nerve
fibers and reduced bone cancer pain-related behaviors
by 50-60%. As the Trk inhibitor has a 50:1 plasma to
CSF ratio, the anti-hyperalgesic actions of the inhibitor
would appear to occur primarily outside the blood brain
barrier. Previous reports have demonstrated that follow-
ing peripheral inflammation and tissue injury, a variety
of inflammatory, immune and stromal cells upregulate
the expression of NGF, brain-derived neurotrophic fac-
tor (BDNF) and neurotrophin-3 (NT-3) whose cognate
receptors are TrkA, TrkB and TrkC respectively. Many
studies have shown that peripheral NGF can drive pain
and have suggested that NGF and perhaps peripherally
released BDNF and NT-3 may play a role in modulating
pain [14,15]. As the present results show that blockade
of all three Trks reduces bone cancer pain, a key ques-
tion is which neurotrophins and Trks are most likely
the major contributors to the generation and mainte-
nance of bone cancer pain.
Previous results have demonstrated that in the adult
NGF can directly activate and sensitize sensory neurons
involved in the conduction of pain originating from the
skin [16,17], viscera and skeleton. NGF is thought to
excite and sensitize sensory neurons by binding to its
cognate receptor TrkA which is expressed by a subpo-
pulation of mostly unmyelinated and thinly myelinated
sensory neurons [18]. NGF binding to TrkA has been
shown to directly activate TrkA-expressing nociceptors
in vivo and in vitro a n dt h a tb i n d i n go fN G Ft oT r k A
directly lowers the threshold for depolarization in these
neurons [19,20]. Additionally, NGF has been shown to
modulate and/or sensitize a variety of neurotransmitters,
receptors, ion channels and structural molecules
expressed by nociceptors [17]. It has also been shown
that NGF lowers the threshold and enhances the
response of nociceptors to mechanical stimuli [21], sug-
gesting that NGF activation of TrkA may play a role in
activating/sensitizing mechanotransducers expressed by
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tissues or tumor cells activates TrkA receptors
expressed on the terminals of C-fibers [18,22] presum-
ably including those innervating the skeleton. Whether
the Trk inhibitor used here is exerting its effect by inter-
fering with the retrograde signal (the internalized NGF/
TrkA complex) that exerts transcriptional control in the
neuronal cell body or by local modulation at the noci-
ceptor terminal is not clear. However, in a model of
b o n ef r a c t u r ep a i n ,w i t hT r ki n h i b i t i o na t2d a y sp o s t
fracture, where nerve sprouting has not yet occurred,
the full analgesic effect is achieved 6-8 hours following
acute administration [23]. These data suggest that local
modulation of nerve fibers must be involved, as trans-
port of the NGF/TrkA from the nerve terminals in the
f e m o r a lf r a c t u r es i t et ot h ecell bodies of sensory neu-
rons that innervate the femur (which are located in the
L1-L3 ganglia) would be expected to take significantly
longer than 8 hours [24].
While there is strong evidence that TrkB receptors
expressed by post-synaptic spinal cord neurons play a
significant role in pain transmission [17] there is signifi-
cantly less agreement about the role of TrkB expressed
by sensory neurons in driving pain. Previous reports
have suggested that TrkB receptors are expressed by a
subpopulation of the DRG, nodose and trigeminal neu-
rons and their terminals in the spinal dorsal horn and
trigeminal nucleus [25-27] and that peripheral inflam-
mation in some tissues results in an increase in BDNF
levels [16]. Interestingly, in pancreatitis BDNF content
was reported to be correlated with pain intensity [28]
and exogenous application of BDNF has been shown to
excite and sensitize some cutaneous nociceptive term-
inals [29] (apparently via TrkB). However, the effects of
Figure 3 Sprouting of sensory nerve fibers in the tumor bearing bone. Confocal images of non-decalcified whole mount preparations of
the femoral periosteum from sham (A) or sarcoma + vehicle mice (B, C) immunostained with calcitonin gene-related peptide (CGRP), a marker
of peptide-rich C-fibers and some A-delta sensory nerve fibers. Note the increased density and disorganized appearance of CGRP
+ nerve fibers
(in red) in the periosteum of the tumor-injected femur (B, C) compared to the periosteum of sham animals (A). This pathological sprouting
pattern is found in the periosteum near viable tumor/stromal cells (C). Confocal images of periosteum were acquired from whole mount
preparations and projected from 280 optical sections at 0.25 μm intervals with a 40x objective.
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any type of chronic pain remain poorly understood [17].
Similarly, there is relatively little evidence to suggest
that peripheral TrkC receptors expressed by myelinated
nerve fibers play a significant role in the generation and
maintenance of pain in the adult. Thus, while local
injection of NT-3 has been reported to induce mild pain
at the injection site [30], other reports suggest that NT-
3 does not sensitize nociceptive primary afferent fibers
[20] and appears to be anti-nociceptive in some pain
models such as complete Freund’s adjuvant-induced
skin inflammation [31].
The above results, together with the present data
demonstrating that the analgesic efficacy of the Trk
inhibitor in blocking bone cancer pain is similar to that
of anti-NGF sequestering therapy, suggest that TrkA
plays the prominent role in driving bone cancer pain
[32]. One unique aspect of the sensory innervation of
bone, which may partially explain why Trk inhibition is
effective in relieving skeletal pain, is that the majority of
C-fibers that innervate the bone are CGRP-expressing
fibers, and nearly all CGRP
+ fibers co-express TrkA
[18,22]. Thus, most C-fibers that innervate both human
[33] and rodent [34] vertebral discs and bone [35]
appear to be CGRP/TrkA expressing fibers and few
unmyelinated non-peptidergic IB4/RET
+ nerve fibers are
present in these tissues [10,35]. Thus, since bone
appears to lack the redundancy of the C-fiber non-pepti-
dergic IB4/RET
+ nerve fibers that are present in skin
[10], blocking TrkA activation may be particularly effica-
cious in relieving bone pain vs. skin pain.
Trks and their involvement in the development of nerve
sprouting and neuroma formation
Although Trks clearly play an essential role in the
growth and survival of sensory neurons in the develop-
ing animal [36,37], much less is known about the role
t h eT r k sp l a yi nt h em a i n t e n a n c ea n ds u r v i v a lo fa d u l t
Figure 4 Tumor-induced formation of neuroma-like structures by sensory nerve fibers. Confocal images of non-decalcified whole mount
preparations of the femoral periosteum from sham (A) or sarcoma + vehicle mice (B, C) immunostained with calcitonin gene-related peptide
(CGRP). Note this mass of nerve fibers has the hallmark of a neuroma-like structure i.e. mass of disordered, blind ending axons that have an
interlacing or whirling morphology (in red) and these neuroma-like formations are only observed in the periosteum of the tumor-injected femur
(B, C) as compared to the periosteum of sham animals (A). Confocal images of periosteum (approximately 70 μm in thickness) were acquired
from whole mount preparations and projected from 280 optical sections at 0.25 μm intervals with a 40x objective.
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be expressed in most tissues at very low levels, whereas
the levels of NGF (and in some tissues BDNF and NT-
3) are dramatically up-regulated by inflammation and/or
injury [14,16]. However, it has been shown that chronic
NGF deprivation (by exogenous administration of an
anti-NGF polyclonal antibody or autoimmunization to
NGF) results in a modest hypoalgesia, where animals
are less sensitive to some thermal and algogenic stimuli
[38]. Whether this hypoalgesic effect observed in rats
with polyclonal antibodies or autoimmunization will
also be observed in humans treated with Trk inhibitors
is unclear as is how much endogenous NGF, BDNF or
NT-3 is required to maintain normal sensory nerve
function in the adult.
The present studies suggest that similar to the tumor,
sensory nerve fibers undergo a highly pathological and
active reorganization as tumor cells invade the bone.
Thus, as the tumor and associated stromal cells invade
the bone, there is significant sprouting by CGRP
+ and
NF200
+ sensory nerve fibers and these sensory nerve
fibers are intermingled among the tumor/stromal cells
that have invaded and remodeled the bone. These newly
sprouted CGRP
+ and NF200
+ n e r v ef i b e r sh a v eav e r y
dense and highly disorganized morphology that is never
observed in the normal bone. In addition to the sprout-
ing of nerve fibers, in approximately 1 out of 2 tumor-
bearing bones we observe the appearance of neuroma-
like structures that looked very similar to neuromas that
have been described in both animals and humans
following traumatic nerve injury. These structures
appear as a disordered mass of CGRP
+ and NF200
+
blind ending axons that generally run parallel to each
other and have an interlacing or whirling morphology
[39,40]. It should be emphasized that we have never
observed these neuroma-like structures in the sham
vehicle-treated or naïve bones. However, these data
would agree with previous findings suggesting that NGF
is involved in neuroma formation and when provided
with the appropriate trophic factor, sensory nerve fibers
can grow at a remarkable pace, sprouting several milli-
meters a day [41].
Previous studies have shown that injury to peripheral
nerves associated with trauma, amputation, compres-
s i o n ,o rs u r g e r yc a nl e a dt op a i n f u ln e u r o m a s
[13,42,43], which have a morphology similar to the
neuroma-like structures observed in the tumor-bearing
mouse bones. In humans, these non-malignant neuro-
mas frequently cause chronic and severe pain [13,43]
and can produce spontaneous ectopic discharges
[44,45] in part by up-regulation of sodium channels
[43,46]. Problematically, painful neuromas can be lar-
gely refractory to current medical treatment [43]. It is
not currently known whether there is up-regulation of
sodium channels and spontaneous discharge by these
neuroma-like structures in the tumor bearing mouse
bone. However, movement may not be required for
these ectopic discharges to occur suggesting that this
mechanism is a possible explanation for spontaneous
breakthrough pain.
Figure 5 Overlay of confocal images of whole mount preparations onto μCT images of bone showing sprouting and neuroma
formation by sensory nerve fibers. Confocal images of whole mount preparations of the femoral periosteum from sham (A) or sarcoma +
vehicle mice (B) immunostained with calcitonin gene-related peptide (CGRP) and overlayed onto uCT images of the bones from which they
were obtained. Confocal images of periosteum (approximately 70 μm in thickness) were acquired from whole mount preparations and projected
from 280 optical sections at 0.25 μm intervals with a 40x objective. Z-stack images of whole mount preparations from four sham or sarcoma +
vehicle mice were acquired, tiled, and overlaid to scale on a three-dimensional micro-CT image of the sham femur (A) and sarcoma + vehicle
femur (B), respectively using AMARA software. Note that the tumor-injected femur (B) has severe cortical bone deterioration and a pathological
reorganization of CGRP nerve fibers (in red) compared to the sham femur (A).
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The present study shows that early/sustained administra-
tion of a small molecule Trk inhibitor attenuates sensory
nerve fiber sprouting, neuroma formation, and bone can-
cer pain-related behaviors. Previous studies have shown
that inappropriate remodeling of sensory nerve fibers,
whether through sprouting or neuroma-like formation,
can give rise to hyperalgesia, allodynia, and spontaneous
ectopic discharges that are perceived as highly painful in
humans [13,43,47]. The present data suggest that early/
sustained administration of therapies that block the NGF/
TrkA axis may be more effective than late administration
in reducing the ectopic sprouting as well as cancer pain.
Methods
Animals
Experiments were performed on a total of 120 adult
male C3H/HeJ mice (Jackson Laboratories, Bar Harbor,
ME), initially at 8 weeks of age, weighing 20-25 g. The
mice were housed in accordance with the National Insti-
tutes of Health guidelines under specific pathogen free
conditions in autoclaved cages maintained at 22°C with
a 12-hour alternating light and dark cycle and were
given autoclaved food and water ad libitum. All proce-
dures were approved by the Institutional Animal Care
and Use Committee at the Minneapolis VA Medical
Center.
Surgical procedure for implantation of cancer cells
Osteolytic murine sarcoma cells were obtained (NCTC
2472, ATCC, Rockville, MD), stably transfected with
green fluorescent protein, maintained and surgically
implanted into the mouse femur as previously described
[32] (Additional file 1 Figure S1).
Treatment with Trk inhibitor (ARRY-470) therapy
The Trk inhibitor (ARRY-470; Array BioPharma,
Boulder, CO) is a potent inhibitor of the tropomyosin
Figure 6 Preventive Trk inhibition reduces CGRP
+ and NF200
+ nerve fiber sprouting and the formation of neuroma-like structures in
the periosteum of tumor-injected mice. Representative confocal images of periosteum from sham (A, D), sarcoma + vehicle (B, E), and
sarcoma + early/sustained ARRY-470 (C, F) mice. Periosteum sections were immunostained with an antibody against CGRP (A-C) and NF200 (D-F).
Note that at day 20 post-tumor cell injection there is significant sprouting and neuroma formation by CGRP
+ (B) and NF200
+ (E) nerve fibers in
sarcoma + vehicle mice. Preventive and maintained administration of ARRY-470 (30 mg/kg; p.o., BID) initiated at day 6 through day 20 post cell
injection significantly reduces the pathological tumor-induced reorganization of sensory CGRP
+ (C) and NF200
+ (F) nerve fibers. Confocal images
were acquired from bone sections (20 μm in thickness) and were projected from 80 optical sections at 0.25 μm intervals with a 40x objective.
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nanomolar cellular inhibiti o no fT r k A( 6 . 5n M ) ,T r k B
(8.1 nM), and TrkC (10.6 nM) and a high level of selec-
tivity over a panel of kinases run at the ATP Km at 1.0
uM and non-kinase receptors [48](Additional file 1
Table S1 and S2). At doses of 10-100 mg/kg ARRY-470
reaches high concentrations in plasma and peripheral
tissues, while the brain concentrations remain negligible,
suggesting very limited crossing of the blood brain
barrier [49]. ARRY-470 at a dose of 30 mg/kg in a
mouse xenograft model derived from HEK cells consti-
tutively expressing active human TrkA showed >90%
inhibition of phosphorylated TrkA at 1 hour and >70%
inhibition over a 12 hour time course [49]. Additionally,
results from previous studies have demonstrated that
administration of 30 mg/kg ARRY-470 significantly
reduced thermal hyperalgesia and mechanical allodynia
in a rat CFA model of inflammation [49].
To evaluate the effect of early vs. late dosing of a Trk
inhibitor on pain-related behaviors, neurochemical
changes and disease progression, treatment with ARRY-
470 (30 mg/kg, p.o., bid) was initiated either when can-
cer-induced pain behaviors became evident (day 6-20
post-sarcoma injection) or after significant disease pro-
gression (day 18-20 post-sarcoma injection).
Behavioral measures of cancer pain
Pain behavior analysis was performed as previously
described [32] (Additional file 1 Methods) and used to
evaluate of the analgesic efficacy of ARRY-470 (30 mg/
kg, p.o.) in attenuating bone cancer-related pain beha-
vior. Assessment of bone cancer pain-related behaviors,
including spontaneous guarding and flinching of the
hind limb, was performed on days 8, 10, 12, 14, 16, 18
and 20 following tumor cell or sham inoculation. Beha-
vioral analyses were performed within 30-60 minutes of
administration of the drug or vehicle (Labrafac;polygly-
colyzed glyceride).
Immunohistochemistry
Mice were sacrificed by carbon dioxide asphyxiation,
delivered using a compressed gas cylinder, at day 20
post sarcoma injection and perfused intracardially with
20 ml of 0.1 M phosphate buffered saline (PBS, pH =
7.4 at 4°C) followed by 30 ml of 4% formaldehyde/12.5%
picric acid solution in 0.1 M PBS (pH = 6.9 at 4°C). Ipsi-
lateral and contralateral femurs were harvested following
perfusion and post-fixed for at least 12 hours in the per-
fusion fixative.
To qualitatively assess the tumor-induced changes in
the density and morphology of sensory nerve fibers that
innervate the periosteum, whole mount preparations
were processed on 20 bones according to the our pre-
viously published procedures [32]. The size of the peri-
osteal whole mount preparation and its attached thin
muscle layer used for immunohistochemistry was
approximately: width = 6 mm; length = 6 mm; thickness
= 0.5 mm.
For quantification, frozen sections were used as the
cross sections allow visualization of the bone’sl a n d -
marks (such as the growth plate), which enable the
observer to locate the same anatomical area when quan-
tifying changes in nerve fibers in different animals.
Figure 7 Preventive administration of ARRY-470 therapy
reduces sarcoma-induced nerve sprouting of CGRP
+ and NF200
+ nerve fibers. At day 20 post cell injection, the density of CGRP
+
(A), NF200
+ (B) nerve fibers is significantly greater in sarcoma +
vehicle-treated mice compared to sham + vehicle-treated mice. This
tumor-induced nerve sprouting is significantly attenuated by early/
sustained administration of ARRY-470 (30 mg/kg; p.o., BID) initiated
at day 6 and maintained through day 20 post tumor cell injection),
but not by late/acute (30 mg/kg; p.o., BID given at day 18 and
maintained through day 20 post tumor cell injection) administration
of ARRY-470. Nerve fiber density was determined by measuring the
total length of nerve fibers per unit volume in the periosteum. Bars
represent the mean ± SEM. *p < 0.05 vs. sham + vehicle, # p < 0.05
vs sarcoma + vehicle. The number of animals was n = 8 for sham, n
= 9 for sarcoma + vehicle, n = 9 for sarcoma + early/sustained
ARRY-470, and n = 7 for sarcoma + late/acute ARRY-470.
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of the femurs was performed as previously described
[32].
Periosteum whole mounts and frozen sections were
processed according to previously published procedures
[32] using a marker of primary afferent sensory neurons
(polyclonal rabbit anti-rat CGRP; 1:10,000; Sigma Che-
mical Co., St. Louis, MO; Catalog number C8198) and a
marker of myelinated primary afferent sensory nerve
fibers (chicken anti-neurofilament 200Kd; NF200,
1:1000; Chemicon, Temecula, CA; Catalog number
AB5539). GFP expression levels did not require amplifi-
cation to quantify tumor progression.
Quantification of nerve fiber density, sprouting and
neuroma formation
The density of CGRP
+ and NF200
+ nerve fibers in the
periosteum following treatment with vehicle or ARRY-
470 was determined by capturing images of these nerve
fibers in periosteal frozen sections using an Olympus
Fluoview FV1000 laser scanning confocal imaging sys-
tem (Olympus America Inc, Melville, NY, software v.
5.0). Approximately 30 separate, 20 μm thick frozen sec-
tions were obtained from each femur. Three images
were obtained for each marker (200× magnification) and
each image was acquired within 2 mm distal from the
proximal femoral growth plate, with images taken from
different sections at least 100 μm apart. The average
area of periosteum that was analyzed was 620 μm
(length), 70 μm (width), 20 μm (depth). The Z-stacked
images were analyzed with Image-Pro Plus v. 6.0 (Media
Cybernetics) and nerve fibers were manually traced to
determine the length of nerve fibers. Nerve sprouting
w a sr e p o r t e da sd e n s i t yo fn e r v ef i b e r sp e rv o l u m eo f
periosteum [32].
To quantify the extent of formation of neuroma-like
structures, frozen sections were examined with a fluor-
escent microscope and these structures were manually
counted and totaled from the entire 20 um thick sec-
tion. Three different sections, each at least 100 um
apart, were evaluated per animal. A neuroma-like struc-
ture was defined as i.) a disordered mass of blind ending
axons (CGRP
+ or NF200
+) that has an interlacing and/
or whirling morphology, ii.) a structure with a size of
more than 10 individual axons that is at least 20 μm
thick and 70 μm long, and iii.) a structure which is
never observed in the periosteum of normal bone
[39,40].
Quantification of tumor growth and tumor-induced bone
destruction
Images of sections from tumor-bearing femurs were
acquired and the total area of intramedullary space and
the percent of intramedullary space occupied by tumor
cells were calculated using Image Pro Plus v6.0 software
(Media Cybernetics, Silver Spring, MD) as previously
described [9]. Area of intramedullary space occupied by
tumor cells is presented as a percentage of total intra-
medullary area. Radiograph images of the medial-lateral
plane of both bones were used to evaluate tumor-
induced bone destruction as previously described [10]
(Additional file 1 Figure S1).
Statistics
A one-way ANOVA was used to compare behavioral
results and immunohistochemical measures between the
experimental groups. For multiple comparisons, the
Fisher’s PLSD (Protected Least Significant Difference)
post hoc test was used. Significance level was set at P <
0.05. In all cases, the investigator responsible for beha-
vioral testing, plotting, measuring, and counting was
blind to the experimental situation of each animal.
Additional material
Additional file 1: Figure S1. Confocal and uCT images of tumor
growth and bone remodeling at day 20 post-tumor cell injection.
Sarcoma+vehicle and sarcoma+ARRY-470 femurs are immunoreactive for
GFP, however, no significant difference in tumor growth or tumor
induced bone destruction was observed. In addition, sham animals
treated with vehicle show no radiographically apparent bone destruction
at day 20, whereas sarcoma+vehicle treated animals show a transition
from the radio-opaque bone tissue to a radiolucent appearance by day
20. Table S1. A broad radiometric protein screen to determine the
selectivity of a Trk inhibitor (ARRY-470) vs. a diverse panel of
kinases. Trk inhibitor ARRY-470 is > 100 fold selective when tested
against a diverse panel of 229 radiometric protein kinases. Table S2. A
broad radioligand screen to determine the selectivity of a Trk
inhibitor (ARRY-470) vs. a diverse panel of receptors, channels, and
transporters. Trk inhibitor ARRY-470 is > 1000 fold selective when tested
against a diverse panel of receptors, channels, and transporters. The Trk
inhibitor ARRY-470 does not show any significant inhibition against this
panel of receptors. In contrast, ARRY-470 inhibits Trks A, B, C with IC50 <
= 11 nM.
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